The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial
Abstract
BACKGROUND Human papillomavirus (HPV) testing on self-collected samples is a potential alternative to HPV testing on clinician-collected samples, but non-inferiority of its clinical accuracy remains to be assessed in the regular screening population. The IMPROVE study was done to evaluate the clinical accuracy of primary HPV testing on self-collected samples within an organised screening setting. METHODS In this randomised, non-inferiority trial, women aged 29-61 years were invited to participate in the study as part of their regular screening invitation in the Netherlands. Women who provided informed consent were randomly allocated (1:1, with a block size of ten stratified by age) to one of two groups: a self-sampling group, in which women were requested to collect their own cervicovaginal sample using an Evalyn Brush (Rovers Medical Devices BV, Oss, Netherlands); or a clinician-based sampling group, in which samples were collected by a general practitioner with a Cervex-Brush (Rovers Medical Devices BV). All samples were tested for HPV using the clinically validated GP5+/6+ PCR enzyme immunoassay (Labo Biomedical Products BV, Rijswijk, Netherlands). HPV-positive women in both groups were retested with the other collection method and triaged by cytology and repeat cytology in accordance with current Dutch screening guidelines. Primary endpoints were detection of cervical intraepithelial neoplasia (CIN) of grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+). Non-inferiority of HPV testing on self-collected versus clinician-collected samples was evaluated against a margin of 90% for the relative sensitivity and 98% for the relative specificity. This study is registered at the Dutch Trial register (NTR5078) and has been completed. FINDINGS Of the 187 473 women invited to participate, 8212 were randomly allocated to the self-sampling group and 8198 to the clinician-based sampling group. After exclusion of women who met the exclusion criteria or who did not return their sample, 7643 women were included in the self-sampling group and 6282 in the clinician-based sampling group. 569 (7·4%) self-collected samples and 451 (7·2%) clinician-collected samples tested positive for HPV (relative risk 1·04 [95% CI 0·92-1·17]). Median follow-up duration for HPV-positive women was 20 months (IQR 17-22). The CIN2+ sensitivity and specificity of HPV testing did not differ between self-sampling and clinician-based sampling (relative sensitivity 0·96 [0·90-1·03]; relative specificity 1·00 [0·99-1·01]). For the CIN3+ endpoint, relative sensitivity was 0·99 (0·91-1·08) and relative specificity was 1·00 (0·99-1·01). INTERPRETATION HPV testing done with a clinically validated PCR-based assay had similar accuracy on self-collected and clinician-collected samples in terms of the detection of CIN2+ or CIN3+ lesions. These findings suggest that HPV self-sampling could be used as a primary screening method in routine screening. FUNDING Ministry of Health, Welfare, and Sport (Netherlands), and the European Commission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arbyn, M., Verdoodt, F., Snijders, P. J. F., Verhoef, V. M. J., Suonio, E., Dillner, L., Minozzi, S., Bellisario, C., Banzi, R., Zhao, F.-H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70570-9 · Cited by 674
Self-citationGok, M., Heideman, D. A. M., van Kemenade, F. J., Berkhof, J., Rozendaal, L., Spruyt, J. W. M., Voorhorst, F., Belien, J. A. M., Babovic, M., Snijders, P. J. F., et al. (2010) · BMJ · doi:10.1136/bmj.c1040 · Cited by 293
Self-citationVerdoodt, F., Jentschke, M., Hillemanns, P., Racey, C. S., Snijders, P. J. F., & Arbyn, M. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.006 · Cited by 275
Self-citationthe Self-Sampling Study Working Group, Giorgi Rossi, P., Marsili, L. M., Camilloni, L., Iossa, A., Lattanzi, A., Sani, C., Di Pierro, C., Grazzini, G., Angeloni, C., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606040 · Cited by 125
Bosgraaf, R. P., Ketelaars, P. J. W., Verhoef, V. M. J., Massuger, L. F. A. G., Meijer, C. J. L. M., Melchers, W. J. G., & Bekkers, R. L. M. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2014.04.011 · Cited by 92
Self-citationCadman, L., Wilkes, S., Mansour, D., Austin, J., Ashdown-Barr, L., Edwards, R., Kleeman, M., & Szarewski, A. (2015) · Journal of Medical Screening · doi:10.1177/0969141314558785 · Cited by 58
Cited by
Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
The IARC Perspective on Cervical Cancer Screening
Bouvard, V., Wentzensen, N., Mackie, A., Berkhof, J., Brotherton, J., Giorgi-Rossi, P., Kupets, R., Smith, R., Arrossi, S., Bendahhou, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmsr2030640 · Cited by 357
Self-citationEfficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women
Barnabas, R. V., Brown, E. R., Onono, M. A., Bukusi, E. A., Njoroge, B., Winer, R. L., Galloway, D. A., Pinder, L. F., Donnell, D., Wakhungu, I., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100056 · Cited by 223
Sargent, A., Fletcher, S., Bray, K., Kitchener, H. C., & Crosbie, E. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025388 · Cited by 75
Why Consider Self-Sampling for Cervical Cancer Screening in Low- and Middle-Income Countries?
(2020) · AMA Journal of Ethics · doi:10.1001/amajethics.2020.116 · Cited by 20
Metadata
- Authors
- Polman, N. J., Ebisch, R. M. F., Heideman, D. A. M., Melchers, W. J. G., Bekkers, R. L. M., Molijn, A. C., Meijer, C. J. L. M., Quint, W. G. V., Snijders, P. J. F., Massuger, L. F. A. G., van Kemenade, F. J., & Berkhof, J.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 20
- Issue
- 2
- Pages
- 229-238
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2910709065
- Cited by
- 225
- References
- 6
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30763-0
- The paper
- Polman, N. J., Ebisch, R. M. F., Heideman, D. A. M., Melchers, W. J. G., Bekkers, R. L. M., Molijn, A. C., Meijer, C. J. L. M., Quint, W. G. V., Snijders, P. J. F., Massuger, L. F. A. G., van Kemenade, F. J., & Berkhof, J. (2019). Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30763-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.